The third batch of "aftershocks"! Should innovative drug pricing be self-threatening?

Guide: Behind the alarming decline in collection varieties, there is more confusion across the industry about the results of ultra-low prices.
, the third batch of national drug collection opened the bid, in the pharmaceutical industry once again set off a storm.
"a bottle of water to buy a year's medicine", "men's happiness no longer worry", "the original research products have been out" ... Behind the staggering drop in collection varieties is the industry's confusion about the results of ultra-low bids.
, at a time when generics must face such low prices, is the future pricing of innovative drugs starting to come at risk? And in the long run, low-cost winning bid for the future development of China's drug development, what will be the impact? The results of the third batch of national selection made the industry boil again this national drug collection results finally came out, a total of 55 varieties of procurement success, the number of drug varieties close to the previous two total.
Further statistics, the minimum winning variety with a price of less than 1 dime is 9 (in general name statistics);
In addition to the above-mentioned varieties, the industry is more surprised by the varieties, for Pfizer"s "Viagra" imitation species Sidinafei, Qilu Pharmaceuticals to each piece of the lowest price of about 2 yuan, become the only winning enterprise, the original research Pfizer out (of course, Viagra's main battleground is not in the hospital).
1.1 Does the limited price of the third batch of generic drugs, the lowest winning variety of generic drugs, affect the development of innovative drugs? The results of this domestic collection, can be said to give all generic drug companies another memorable lesson, then, generic drug low-cost evaluation, for the future trend of innovative drugs, will have an impact? Here, let's start with the types of new drug companies in our country.
Henyep Securities Research Institute has divided China's innovative pharmaceutical enterprises into 1.0/2.0/3.0 models.
1.0 model, that is, the old large pharmaceutical companies from imitation to creation, and gradually layout innovative drug fields, such as Hengrui;
1.0 old large pharmaceutical companies, although most have been listed for financing, but in the early years have been initially completed capital accumulation, generic drug business is often an important economic pillar of new drug development, at this time encountered such a price-killing collection, although not hurt, but will certainly make adjustments;
2.0/3.0 type of pharmaceutical enterprises innovative drug development, the funds mainly from financing, generic drugs in the collection of fighting, theoretically short-term will not affect the development process of innovative drugs.
1.2 Who will set the price of innovative drugs for research and development by domestic listed pharmaceutical companies in 2019? Today's "volume procurement, low-cost winning bid", although the industry "suffering", but also after many years of market research and policy control, especially in terms of price policy, but also the introduction of the "Interim Measures for drug price management" (1996), "Pharmaceutical Government Pricing Measures" (2000), "Drug Price Differential Rules" (2011) and so on ... For innovative drugs, the price of new drugs usually comes more from pharmaceutical companies.
In principle, the individual pricing of enterprises should be based on cost accounting, but because it is difficult for government departments to verify the true cost of new drugs from research and development to development to market, the individual pricing of new drugs is actually independent pricing.
drug companies in order to quickly recover up-front costs, while carrying out other projects, will generally be priced higher to prevent subsequent generic drug market share.
, such as Grewe in "Pharmaceutical God" and SMA in the Ice Bucket Challenge.
But if the price of new drugs is entirely determined by the Government, in order to improve the overall welfare of drug consumers, it is bound to impose price caps on drug prices, and if there is no lower limit, new drugs will face the possibility of cabbage prices.
high risk no longer has high returns, investors will naturally withdraw from the industry, in the long term, more disadvantages.
And a large number of domestic and foreign scholars have been studying this for many years, and the conclusions are mostly that "too low drug pricing will ultimately affect the pharmaceutical industry's investment decision-making, so that research and development funds will be reduced accordingly", "the appropriate increase in drug prices will be conducive to the development of China's pharmaceutical enterprises", "the balance between the price of innovative drug control and research and development expenditure can not only ensure the effectiveness of patients, but also ensure the reasonable level of investment in research and development of pharmaceutical companies" ... Japan's drug pricing policy is very worthy of reference! Whether It is drug research and development in Japan, or related drug policies, it is worth learning from.
the early 2000s, Japan set prices for new drugs based on cost calculations and adjusted prices for similar products and based on average foreign prices.
The price of new drugs is reviewed, the price of new dosage forms/new specifications is determined several times a year, and price adjustments are made every 2 years for all varieties included in the drug price benchmark, for all wholesalers, some hospitals and clinics, for a period of 1 month.
government pricing of drugs is basically the same as the actual selling price of the market because of the focus on market research.
japan's innovative drugs are approved for sale, companies can apply for new drug prices.
According to the basic price of the prior investigation, the relevant departments and enterprises of the Ministry of Health, Labour and Industry shall hold a hearing, after which the relevant departments shall make an approved draft, and then another organization shall set the price, and the final price shall be reported to the Central Medical Insurance Association for approval.
Japan's original drug policy is similar to most foreign countries, there will be a certain exclusive period, after the exclusive period of generic drugs on the market;
as a whole, Japan's drug price-setting mechanism will be better compound market mechanism, and will be more flexible to adjust.
Summarize, the author believes: 1) generic drugs ultra-low-cost winning bid collection, will inevitably have a certain impact on the innovative drug business, many companies will adjust the company's innovative drug business research and development investment according to the results of the collection; Economic perspective or the result of risk-benefit ratio, in the face of such a wide price difference between the same kind, it is difficult for ordinary people to choose the new drugs just listed; 3) new drug companies need to dig deeper into market demand and changes, in order to more reasonable calculation of the market price of new drugs; 4) the continued lowest price winning bid, domestic drug research and development, more harm than good.
.